Sarkis Mazmanian, Ph.D.
InvestorScientific Advisor at Time BioVentures
About
Sarkis K. Mazmanian is the Luis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at Caltech and an Investigator of the Heritage Medical Research Institute. He earned his Ph.D. in microbiology and immunology at UCLA, held a Helen Hay Whitney Postdoctoral Fellowship, and was an Assistant Professor at Harvard Medical School before joining Caltech in 2006. His lab studies beneficial gut microbiome molecules as potential therapies for immunologic and neurologic disorders, including inflammatory bowel disease, autism, and Parkinson's disease.
Invests in
Biotech
Colleagues at Time BioVentures
Bradford Cornell
Advisor at Time BioVentures
D.A. Wallach
General Partner at Time BioVentures
Daniel L. Vasella, M.D.
Advisor at Time BioVentures
Jay Flatley
Advisor at Time BioVentures
Jim Allison, Ph.D.
Scientific Advisor at Time BioVentures
Leonard Schaeffer
Advisor at Time BioVentures
Pam Sharma, M.D., Ph.D.
Scientific Advisor at Time BioVentures
Paul McEwan
Scientific Advisor at Time BioVentures
Frequently asked questions
- Who is Sarkis Mazmanian, Ph.D.?
- Sarkis K. Mazmanian is the Luis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at Caltech and an Investigator of the Heritage Medical Research Institute. He earned his Ph.D. in microbiology and immunology at UCLA, held a Helen Hay Whitney Postdoctoral Fellowship, and was an Assistant Professor at Harvard Medical School before joining Caltech in 2006. His lab studies beneficial gut microbiome molecules as potential therapies for immunologic and neurologic disorders, including inflammatory bowel disease, autism, and Parkinson's disease.
- Where does Sarkis Mazmanian, Ph.D. work?
- Sarkis Mazmanian, Ph.D. is Scientific Advisor at Time BioVentures.
- What does Sarkis Mazmanian, Ph.D. invest in?
- Sarkis Mazmanian, Ph.D. invests in Biotech.
Are you in our directory? — or find your own page and tap it there to see your paths to every investor.